“Impact of Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, on Psoriasis in Patients With Active Psoriatic Arthritis: Results from a Phase 2 Trial”. 2024. SKIN The Journal of Cutaneous Medicine 8 (2): s383. https://doi.org/10.25251/skin.8.supp.383.